Today: 9 June 2026
Archer Aviation stock pops in premarket after Nvidia IGX Thor AI tie-up — here’s what’s next

Archer Aviation stock pops in premarket after Nvidia IGX Thor AI tie-up — here’s what’s next

New York, Jan 9, 2026, 08:08 EST — Premarket

Archer Aviation Inc shares were up 2.6% at $8.94 in premarket trading on Friday after the company unveiled an AI collaboration with Nvidia at the CES technology show in Las Vegas. The stock ended Thursday up 3.4% at $8.71, after trading between $8.44 and $9.01 on volume of about 50 million shares.

The move matters because Nvidia-linked headlines are still moving prices in smaller, speculative names, especially when the story touches safety and autonomy rather than data-center servers.

For Archer, the question isn’t just chips. Investors want to know whether software and computing can help close the gap between prototype aircraft and regulated commercial service, where delays are common and expensive.

Archer said it plans to develop and deploy aviation AI using Nvidia’s IGX Thor platform, a “safety-capable” onboard computing module designed for real-time processing in safety-critical settings. The company said it expects to showcase the integration at its recently acquired Hawthorne airport site in central Los Angeles and will target pilot safety, airspace integration and autonomy-ready flight controls; CEO Adam Goldstein said the Nvidia stack would help it “accelerate toward safer, smarter aircraft systems.” Archer Aviation

The company is building “Midnight,” an electric vertical takeoff and landing aircraft — eVTOL in industry shorthand — aimed at short-hop urban routes. Traders have treated the space as a headline market, with partnerships and regulatory progress driving sharp, short-lived swings.

Rivals were mixed before the open: Joby Aviation fell about 2%, Vertical Aerospace rose about 4% and Eve Air Mobility was little changed, while Nvidia shares were down about 2%.

But a deal with a big-name chipmaker does not settle the hard parts. Archer still needs certification, production readiness and enough cash to bridge to revenue — any slip can force dilution or push timelines out again.

The next catalyst is the company’s next quarterly update and any fresh detail on certification and spending. TradingView’s earnings calendar lists Archer’s next report date as March 4.

Stock Market Today

  • SpaceX IPO Raises Twice Planned Amount as Order Books Oversubscribe Ahead of Nasdaq Debut
    June 9, 2026, 9:00 AM EDT. SpaceX's initial public offering (IPO) has been significantly oversubscribed, with demand reaching approximately $150 billion, double the $75 billion the company aims to raise. Several institutional investors placed orders exceeding $10 billion each, signaling strong market interest ahead of SpaceX's planned Nasdaq debut. The high demand underscores investor confidence in the aerospace firm's growth prospects amid its expansion in satellite and space exploration sectors.

Latest articles

AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus

Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus

9 June 2026
Grab shares hovered near $3.33 in pre-market trading after unveiling a new Singapore merchant programme and Taiwan partner commitments, as investors weigh growth initiatives against regulatory hurdles and consumer spending pressure; the stock’s muted move reflects ongoing uncertainty around its proposed foodpanda Taiwan acquisition and potential margin impacts from promotions.
Nokia stock rises after Hisense patent deal ends litigation; investors watch next moves
Previous Story

Nokia stock rises after Hisense patent deal ends litigation; investors watch next moves

Kohl’s stock slides 5% as tariff ruling delay hits retailers; KSS traders eye Jan. 14
Next Story

Kohl’s stock slides 5% as tariff ruling delay hits retailers; KSS traders eye Jan. 14

Go toTop